(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said. Reuters could not immediately confirm the FT report. (Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
London (dpa) - Stadium-hopping rock giants U2 have dropped a new radio-ready single and accompanying…
On their new album "Foreign Tongues", the Rolling Stones are brimming with energy and a…
Stroking a dog or riding a horse can release oxytocin and ease stress and anxiety.…
By Hanna Rantala LONDON, July 7 (Reuters) - Rock musical "Jesus Christ Superstar" returns to…
By Jody Godoy July 7 (Reuters) - The Oregon attorney general will ask a court…
By Hanna Rantala LONDON, July 7 (Reuters) - Rock musical "Jesus Christ Superstar" returns to…